InSphero, a spin-out of ETH Zurich and Zurich University, has entered a collaboration agreement with Protea Biosciences. The deal will see the two companies combine each other’s 3D technologies.
InSphero’s technology allows in vitro toxicology and efficacy studies. Its 3D organotypic microtissues provide models for liver, pancreas, brain and tumours, which provide a much higher level of accuracy to predict the effects of drug candidates than 2D cell cultures.
The partnership will allow InSphero and Protea to create 3D molecular…
